Elza Muscelli1, Brenno Astiarraga1, Elisabetta Barsotti1, Andrea Mari2, Freimut Schliess3, Leszek Nosek3, Tim Heise3, Uli C Broedl4, Hans-Juergen Woerle4, Ele Ferrannini5,6. 1. Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100, Pisa, Italy. 2. C.N.R. Institute of Neuroscience, Padua, Italy. 3. Profil, Neuss, Germany. 4. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany. 5. Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100, Pisa, Italy. ferranni@ifc.cnr.it. 6. CNR Institute of Clinical Physiology, Pisa, Italy. ferranni@ifc.cnr.it.
Abstract
AIMS/HYPOTHESIS: Sodium glucose co-transporter 2 (SGLT2) inhibitors lower glycaemia by inducing glycosuria, but raise endogenous glucose production (EGP). Metformin lowers glycaemia mainly by suppressing EGP. We compared the effects of the SGLT2 inhibitor empagliflozin in treatment-naive (TN) and metformin pretreated (Met) patients with type 2 diabetes. METHODS: A total of 32 TN and 34 patients on a stable dose of metformin, two subgroups of a study that we previously reported, received a mixed meal with double-tracer glucose administration and indirect calorimetry at baseline, after a single 25 mg dose of empagliflozin, and after 4 weeks of treatment with empagliflozin 25 mg/day. RESULTS: At baseline, compared with the TN group, the Met group had higher fasting glycaemia (9.1 ± 1.7 vs 8.2 ± 1.3 mmol/l), lower fasting and postmeal insulin secretion, lower beta cell glucose sensitivity (37 [18] vs 58 [43] pmol min(-1) m(-2) [mmol/l](-1), median [interquartile range]) and insulin:glucagon ratio, and higher fasting EGP (15.9 [4.3] vs 12.1 [2.7] μmol kgFFM (-1) min(-1)). Change from baseline in fasting EGP after single dose and 4 weeks of treatment with empagliflozin was similar in the Met and TN groups (19.6 [4.2] and 19.0 [2.3] in Met vs 16.2 [3.6] and 15.5 [3.2] μmol kgFFM (-1) min(-1) in TN for acute and chronic dosing, respectively). Beta cell glucose sensitivity increased less in Met than TN patients, whereas substrate utilisation shifted from carbohydrate to fat more in Met than TN patients. CONCLUSIONS/ INTERPRETATION: At baseline, Met patients with type 2 diabetes had more advanced disease than TN patients, featuring worse beta cell function and higher EGP. Empagliflozin induced similar glycosuria and metabolic and hormonal responses in Met and TN patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT01248364; European Union Clinical Trials Register 2010-018708-99.
AIMS/HYPOTHESIS: Sodium glucose co-transporter 2 (SGLT2) inhibitors lower glycaemia by inducing glycosuria, but raise endogenous glucose production (EGP). Metformin lowers glycaemia mainly by suppressing EGP. We compared the effects of the SGLT2 inhibitor empagliflozin in treatment-naive (TN) and metformin pretreated (Met) patients with type 2 diabetes. METHODS: A total of 32 TN and 34 patients on a stable dose of metformin, two subgroups of a study that we previously reported, received a mixed meal with double-tracer glucose administration and indirect calorimetry at baseline, after a single 25 mg dose of empagliflozin, and after 4 weeks of treatment with empagliflozin 25 mg/day. RESULTS: At baseline, compared with the TN group, the Met group had higher fasting glycaemia (9.1 ± 1.7 vs 8.2 ± 1.3 mmol/l), lower fasting and postmeal insulin secretion, lower beta cell glucose sensitivity (37 [18] vs 58 [43] pmol min(-1) m(-2) [mmol/l](-1), median [interquartile range]) and insulin:glucagon ratio, and higher fasting EGP (15.9 [4.3] vs 12.1 [2.7] μmol kgFFM (-1) min(-1)). Change from baseline in fasting EGP after single dose and 4 weeks of treatment with empagliflozin was similar in the Met and TN groups (19.6 [4.2] and 19.0 [2.3] in Met vs 16.2 [3.6] and 15.5 [3.2] μmol kgFFM (-1) min(-1) in TN for acute and chronic dosing, respectively). Beta cell glucose sensitivity increased less in Met than TN patients, whereas substrate utilisation shifted from carbohydrate to fat more in Met than TN patients. CONCLUSIONS/ INTERPRETATION: At baseline, Met patients with type 2 diabetes had more advanced disease than TN patients, featuring worse beta cell function and higher EGP. Empagliflozin induced similar glycosuria and metabolic and hormonal responses in Met and TN patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT01248364; European Union Clinical Trials Register 2010-018708-99.
Entities:
Keywords:
Empagliflozin; Endogenous glucose production; Glycosuria; Metformin; Type 2 diabetes
Authors: A Liakos; T Karagiannis; E Athanasiadou; M Sarigianni; M Mainou; K Papatheodorou; E Bekiari; A Tsapas Journal: Diabetes Obes Metab Date: 2014-05-28 Impact factor: 6.577
Authors: Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg Journal: J Am Soc Nephrol Date: 2010-07-08 Impact factor: 10.121
Authors: J Rosenstock; L J Seman; A Jelaska; S Hantel; S Pinnetti; T Hach; H J Woerle Journal: Diabetes Obes Metab Date: 2013-08-22 Impact factor: 6.577
Authors: Tongzhi Wu; Sony S Thazhath; Michelle J Bound; Karen L Jones; Michael Horowitz; Christopher K Rayner Journal: Diabetes Res Clin Pract Date: 2014-08-12 Impact factor: 5.602
Authors: Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Uli C Broedl; Hans J Woerle Journal: Diabetes Care Date: 2014-04-10 Impact factor: 19.112